Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Firsekibart combined with febuxostat for recurrent chronic tophaceous gout
ChiCTR2600132644Phase 4Not yet recruiting
- Sponsor
- The First Affiliated Hospital of USTC
- Start
- Sep 2026
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of genakumab, febuxostat and compound betamethasone in gout (2 arms), sponsored by The First Affiliated Hospital of USTC. Primary endpoint: Number of gout relapses within 24 weeks. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
genakumabfebuxostatcompound betamethasone
03
Conditions
gout
Beyond the preview
Go deeper on ChiCTR2600132644.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600132644.